In pre-clinical models of obesity and diabetes, MetAP2 inhibitors have been shown to inhibit fat mass expansion and improve glycemic control, and reduce food intake in mice [14–16]. Here, METAP2 is linked to obesity due to melanocortin 4 receptor deficiency.